

MDMA en prosociaal gedrag: De rol van de 2a-serotonine receptor.

Gepubliceerd: 08-11-2012 Laatste bijgewerkt: 15-05-2024

We hypothesize that: 1. The MDMA effect on prosocial behavior is context dependent (e.g. influence by 'extra' social information and importance of the reward) and; 2. These effects will be absent when MDMA is combined with ketanserin.

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON29427

Bron

NTR

Verkorte titel

MDMA5-HT2aRPSB

Aandoening

Neurobiological mechanism underlying MDMA-induced prosocial behaviour

Ondersteuning

Primaire sponsor: Maastricht University, K. P. C. Kuypers

Overige ondersteuning: NWO

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Cognitive and affective empathy.

Toelichting onderzoek

Achtergrond van het onderzoek

Rationale:

MDMA exerts positive effects on social behaviour. The neurobiological mechanism underlying these effects is to date not known. There is some evidence that the 5-HT_{2a} receptor might play a role in this mechanism. The fundamental knowledge that is generated by this study can be implemented in research into the neurobiology of certain diseases in which prosocial behaviour or empathy is lacking, e.g. autism spectrum disorders, social anxiety disorder.

Objective:

First, we would like to investigate the effects of MDMA on social cognition and interaction by means of paradigms which take context into account. Second, we would like to investigate the role of the 5-HT_{2a} receptor in these effects. We hypothesize that (1) the MDMA effect on prosocial behavior is context dependent (e.g. influence by 'extra' social information and importance of the reward) and that (2) these effects will be absent when MDMA is combined with ketanserin.

Study design & Intervention:

Both aims will be accomplished by conducting a four-way crossover study including single doses and combinations of MDMA-75mg and the 5-HT_{2a} blocker ketanserin-40 mg in order to study the effects of the substances alone and the effects of MDMA after blockade of the 5-HT_{2a} receptors.

Study population:

Participants will be maximally twenty-four (N=20 + 4 drop-outs) recreational ecstasy users (3 < lifetime use <200) aged between 18 and 35 years. All subjects will be medically screened.

Main study parameters/endpoints:

Main study endpoints will be subjective and objective measures of cognitive and affective empathy. Tasks to assess this are the inter-reactivity index and the multifaceted empathy

test.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Participants will go through 4 sessions of 4h15'. The load for a subject during a test day is restricted to (1) taking study treatments, (2) taking 3 blood samples, (3) filling out questionnaires and doing computer tasks (duration: $\pm$ 75 minutes). During the periods that they are not tested (breaks), they will be seated in a waiting room where they will be in close contact with one of the researchers. In case they experience (medical) complaints, the medical supervisor will be contacted.

Doel van het onderzoek

We hypothesize that:

1. The MDMA effect on prosocial behavior is context dependent (e.g. influence by 'extra' social information and importance of the reward) and;
2. These effects will be absent when MDMA is combined with ketanserin.

Onderzoeksopzet

Prior to participation, subjects undergo a physical examination (blood, ElectroCardioGram). When there is no medical objection for participation, subjects will come for a training day. During this training day they will be explained the procedure of a test day and be familiarized with the cognitive tests in the laboratory.

Test day (Table 4). Upon arrival at 9:00 at our testing facilities, subjects will be screened for drugs, in urine and alcohol, in breath. They will be asked whether they had enough sleep the day before (questionnaire) and whether they abstained from alcohol and caffeinated beverages 24h prior to the testing day. Between 9:00 and 9:30 they will be offered a standard meal, followed by PreTreatment (Ketanserin/Placebo) at 9:30. Just before they receive the PreTreatment, blood samples will be collected and blood pressure and heart rate will be assessed. At 10:00 participants will receive their treatment respectively MDMA or Placebo. In between subjects will be seated in a waiting room, equipped with a TV. At 11:20 a second blood sample will be taken and blood pressure and heart rate will be assessed. Between 11:30-13:00 testing will take place in the laboratory. At the end of the test battery, blood samples will be collected and heart rate and blood pressure will be assessed (See table 4).

The minimum period between successive treatments will be 7 days. Subjects will be compensated for their participation by means of a monetary reward.

Onderzoeksproduct en/of interventie

1. MDMA-75 mg;
2. Ketanserin-40mg;
3. MDMA-75mg + Ketanserin-40 mg;
4. Double placebo.

Contactpersonen

Publiek

P.O. Box 616

K.P.C. Kuypers
Universiteit Maastricht, Fac. FPN. Dept. NP&PP, PB 616
Maastricht 6200 MD
The Netherlands
+31 (0)433881902

Wetenschappelijk

P.O. Box 616

K.P.C. Kuypers
Universiteit Maastricht, Fac. FPN. Dept. NP&PP, PB 616
Maastricht 6200 MD
The Netherlands
+31 (0)433881902

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Experience with the use of MDMA (maximally 200 times in total, minimally 3 times in total; and at least once in the past 12 months): This will be assessed by means of a drug history questionnaire and an interview by the medical supervisor;

2. Age between 18-35 years;
3. Free from medication (except oral contraception);
4. Good physical health as determined by examination and laboratory analysis;
5. Absence of any major medical, endocrine and neurological condition;
6. Normal weight, body mass index (weight/height²) between 18 and 28 kg/m²;
7. Written Informed Consent;
8. Fluent Dutch speaker (as some tasks require this).

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. History of drug abuse (other than the use of MDMA) or addiction;
2. Current or history of psychiatric disorder;
3. Women: Pregnancy or lactation;
4. Cardiovascular abnormalities as indicated by:
 - A. The medical questionnaire and/or;
 - B. The standard 12-lead ECG.
5. Excessive drinking (> 20 alcoholic consumptions a week);
6. Hypertension (diastolic > 90; systolic > 140).

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Cross-over
Toewijzing:	Gerandomiseerd
Blindering:	Dubbelblind

Controle: Placebo

Deelname

Nederland
Status: Werving gestart
(Verwachte) startdatum: 30-01-2013
Aantal proefpersonen: 20
Type: Verwachte startdatum

Ethische beoordeling

Positief advies
Datum: 08-11-2012
Soort: Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 37277
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL3536
NTR-old	NTR3691
CCMO	NL42465.068.12
ISRCTN	ISRCTN wordt niet meer aangevraagd.
OMON	NL-OMON37277

Resultaten

Samenvatting resultaten

N/A